Trulance
(Plecanatide)Phase 3Peptide
Trulance is one of 34 small molecule programs targeting Constipation. It is currently in Phase 3.
2
Indications
13
Total Trials
1
Active Trials
33
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
10
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
185 competitors in Irritable Bowel Syndrome
#DrugCompanyPhaseTrials
1Lialda
TakedaPhase 3
Xifaxan
SSalix
Phase 3
Zofran
NovartisPhase 3
Amitiza
SSucampo Pharma Americas, LLC
Phase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Zarontin
PParkedale
Phase 3
Mesalazine
FerringPhase 3
Saccharomyces Boulardii
BBiocodex
Phase 3
Trulance
SSalix
Phase 3
Lotronex
LLegacy Health System
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Irritable Bowel Syndrome4 trials
Constipation4 trials
Show 1 more trial
Breast1 trial
Regulatory
FDA Approval Timeline[4]
Jan 19, 2017
TRULANCE
NDA NDA208745
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Plecanatide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]